VA Office of Research and Development
research.va.govLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
1,733
Active
464
Phase 3
83
Total enrollment
3,619,792
Pipeline matrix
Showing 40 of 119 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Empagliflozin | — | — | — | — | 4 | ||
| Methylphenidate | — | — | — | — | 4 | ||
| Acetazolamide | — | — | — | 3 | |||
| Suvorexant | — | — | — | — | — | 2 | |
| Pimavanserin | — | — | — | — | 2 | ||
| Finasteride | — | — | — | — | 3 | ||
| Quetiapine | — | — | — | — | — | 2 | |
| Metformin XR | — | — | — | — | — | 1 | |
| Lorazepam 1 mg | — | — | — | — | — | 1 | |
| Teriparatide or human parathyroid hormone (PTH) 1-34 | — | — | — | — | — | 1 | |
| Cinacalcet | — | — | — | — | — | 1 | |
| Pentoxifylline | — | — | — | — | — | 1 | |
| Sublingual buprenorphine with naloxone | — | — | — | — | — | 1 | |
| Injectable subcutaneous buprenorphine | — | — | — | — | — | 1 | |
| Trazodone + PAP therapy | — | — | — | — | — | 1 | |
| Oxygen + PAP therapy | — | — | — | — | — | 1 | |
| Clopidogrel treatment | — | — | — | — | — | 1 | |
| Aspirin treatment | — | — | — | — | — | 1 | |
| mirabegron | — | — | — | — | — | 1 | |
| Medication optimization | — | — | — | — | — | 1 | |
| Colchicine | — | — | — | — | — | 1 | |
| Acetazolamide + supplemental oxygen + PAP therapy | — | — | — | — | — | 1 | |
| Zolpidem + PAP therapy | — | — | — | — | — | 1 | |
| Buspirone + PAP therapy | — | — | — | — | — | 1 | |
| Apixaban | — | — | — | — | — | 1 | |
| Rivaroxaban | — | — | — | — | — | 1 | |
| Atomoxetine | — | — | — | — | — | 1 | |
| Motivation-Phase Varenicline | — | — | — | — | — | 1 | |
| Motivation-Phase Nicotine Mini-Lozenge | — | — | — | — | — | 1 | |
| Cessation-Phase Combination Nicotine Replacement Therapy | — | — | — | — | — | 1 | |
| Cessation-Phase Varenicline | — | — | — | — | — | 1 | |
| Carvedilol | — | — | — | — | 2 | ||
| Prazosin | — | — | — | — | — | 2 | |
| Somatropin | — | — | — | — | — | 1 | |
| Corticosteroid Injection given in A-B order | — | — | — | — | — | 1 | |
| Procedure: Corticosteroid Injection given in B-A order | — | — | — | — | — | 1 | |
| Semaglutide | — | — | — | — | — | 1 | |
| Psilocybin | — | — | — | — | — | 1 | |
| Metformin ER | — | — | — | — | — | 1 | |
| Goserelin, Histrelin, Leuprolide & Triptorelin | — | — | — | — | — | 1 |
79 more active programs hidden
Next readouts
- 2024-11-30
- 2025-06-30
- 2025-12-31
- 2026-01-01
- 2026-02-02
- 2026-04-30
- 2026-05-01
- 2026-06-30
- 2026-07-06
- 2026-07-31
Top conditions
- Stroke74
- PTSD70
- Depression64
- Posttraumatic Stress Disorder57
- Obesity46
- Spinal Cord Injury44
- Schizophrenia43
- Stress Disorders, Post-Traumatic36
Frequently asked questions about VA Office of Research and Development
- How many clinical trials does VA Office of Research and Development have on ClinicalTrials.gov?
- VA Office of Research and Development is listed as the lead sponsor on 1,733 clinical trials in ClinicalTrials.gov, 464 of which are currently active (recruiting, enrolling, or ongoing).
- How many of VA Office of Research and Development's trials are in Phase 3?
- 83 of VA Office of Research and Development's trials are in Phase 3, spread across 119 active drug programs.
- What therapeutic areas does VA Office of Research and Development focus on?
- VA Office of Research and Development's most-studied conditions on ClinicalTrials.gov are Stroke, PTSD, Depression, Posttraumatic Stress Disorder, Obesity.
- When are VA Office of Research and Development's next clinical trial readouts?
- VA Office of Research and Development has 10 upcoming primary-completion readouts tracked here; the soonest is “A Pragmatic Trial to Determine the Benefit of Behaviorally Enhanced Exercise Incentives and Corticosteroid Injections in Osteoarthritis of the Knee Marching On for Veterans With Osteoarthritis of the Knee”, expected around 2024-11-30.